Construction tracker puts Lilly's GLP-1 build-out above $13 billion at its Indiana site
Lilly and Novo Nordisk are pouring tens of billions into GLP-1 factories, which could affect how reliably these drugs are supplied in the US, though no source says when or whether that changes prices.
Eli Lilly has committed more than $13 billion to its manufacturing complex in Lebanon, Indiana, and has $3.2 billion of international construction underway, with another $3.7 billion in various stages of planning and engineering, according to a GLP-1 construction tracker published Aug. 27, 2026 [1].
The tracker, from Industrial Info Resources, sizes the building wave around GLP-1 drugs, which include Lilly's tirzepatide products Mounjaro and Zepbound and Novo Nordisk's semaglutide products Ozempic and Wegovy [1]. A separate report published Sept. 7, 2026 says Lilly will more than double its US manufacturing investment since 2020, surpassing $50 billion, and build four new pharmaceutical manufacturing sites [2].
Where the money is going
At Lebanon, the more than $13 billion figure covers development and production of a wider range of products besides GLP-1s, though GLP-1s feature prominently in the plans [1].
Several projects are tied to orforglipron, Lilly's experimental oral GLP-1. Those include a Houston, Texas site that will produce small-molecule active pharmaceutical ingredients for oral GLP-1 drugs still needing regulatory authorization, and a building addition in Puerto Rico that broke ground and is expected to begin contributing to oral-dose GLP-1 production in 2029, accompanied by a solar power array [1]. Lilly's $6 billion grassroot campus in Huntsville, Alabama also includes orforglipron in its plans [1]. The tracker flagged a planned oral-dose GLP-1 plant in the Netherlands with an initial budget of more than $1.5 billion, with the possibility of doubling that investment later [1].
For injectables, Lilly has a seven-building campus planned in Fogelsville, Pennsylvania, where Zepbound and Mounjaro play a large role, along with the experimental weight-loss drug retatrutide [1].
Novo Nordisk is putting another $4.1 billion into its Clayton, North Carolina campus, roughly doubling its square footage in the state with 1.4 million square feet of additional building space [1]. In a 2024 deal worth $11 billion, it acquired Catalent and its three fill-finish sites, in Bloomington, Indiana; Anagni, Italy; and Brussels, Belgium [1]. Novo Nordisk has about $9.1 billion of construction underway outside the US, mostly in Denmark, with more on the books [1].
According to the Sept. 7 report, three of Lilly's four new US sites will focus on active pharmaceutical ingredient manufacturing, and the fourth will expand its network for injectable therapies [2]. That investment is expected to generate more than 3,000 high-skilled jobs, with nearly 10,000 construction jobs during building [2]. Lilly's prior domestic capital commitments between 2020 and 2024 totaled $23 billion and included sites in Research Triangle Park and Concord, North Carolina; the LEAP Innovation District and the Lilly Medicine Foundry in Lebanon, Indiana; modernization in Indianapolis; and a site in Kenosha County, Wisconsin [2]. Locations for the four newly announced sites have not been disclosed [2].
Why it matters for patients
Most GLP-1 drugs used in the US are made by these two companies, and the tracker frames the spending as a response to demand. A Gallup News poll published in July found that 11% of US adults were taking GLP-1 drugs for weight loss in 2026, up from 3% in 2024, and 15% reported using them for weight loss at some point in their lives [1]. A study led by Cornell University found that households with at least one GLP-1 user saw a 6% reduction in grocery bills within six months [1].
More capacity for ingredients and for filling and finishing injectable doses is what these projects add. Whether that translates into fewer shortages, wider insurance coverage or lower out-of-pocket costs has not been reported, and none of the sources states a price effect. Orforglipron has not been authorized for sale in the US [1], so those plants are being built ahead of any approval decision.
What happens next
The only production date attached to an oral GLP-1 project is 2029, when the Puerto Rico addition is expected to begin contributing [1]. Completion dates for Lebanon, Huntsville and the Netherlands plant are not given in the tracker [1]. The Netherlands investment could be doubled at a later point [1]. For Novo Nordisk, the tracker says more construction outside the US is on the books beyond the $9.1 billion underway [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.